How did one of the ambitious gene editing startups in biotech come together? What lessons does Harvard University professor and biotech veteran Vicki Sato have about closing the gender gap after spending “most of her career” as the only woman in the room? And what would it take to get organ systems on tiny microchips not just adopted by pharma, but approved by the FDA as a replacement for other preclinical drug testing methods?
These are just a few questions that our speakers answered last week at the latest installment of “Boston’s Life Science Disruptors” at the Koch Institute for Integrative Cancer Research at MIT. A packed house took part in interactive chats on three topics; you can get a little taste of the festivities in the slideshow above.
Thanks first to our attendees and our speakers: Koch biological and mechanical engineering professor Scott Manalis; Wyss Institute founding director Don Ingber; Emulate president and CSO Geraldine Hamilton; Harvard professor of management practice Vicki Sato; Polaris Partners founding partner Terry McGuire; Koch executive director Anne Deconinck; Intellia Therapeutics founder and CEO Nessan Bermingham; and Atlas Venture partner Jean-Francois Formela.
Thanks also to our event host the Koch Institute; and gold sponsors ALT and Bayer; silver sponsors The Richmond Group, Danforth Advisors, Sunstein Kann Murphy & Timbers LLP, and WuXi AppTec. Also a thank you to our event partners: the Association for Women in Science, and Massachusetts Life Sciences Center; our national partner Alexandria Real Estate Equities; and our charter underwriter Biogen.
And as always a tip of the cap to Keith Spiro of Keith Spiro Photography for the photos—hope you all enjoy them.